Home Depot Inc vs GeneDx Holdings Corp — how do they compare? Home Depot Inc trades at $353.13 (market cap $349.77B), while GeneDx Holdings Corp trades at $81.98 (market cap $2.32B). The key difference: Home Depot Inc is far larger — about 150.8× GeneDx Holdings Corp's market cap, and Home Depot Inc pays a 2.66% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| HD | WGS | |
|---|---|---|
Market Cap | $349.77B | $2.32B |
Sector | Consumer Cyclical | Technology |
52-Week High | $423.42 | $167.51 |
52-Week Low | $297.51 | $34.51 |
Enterprise Value | $411.32B | $2.35B |
Dividend Yield | 2.66% | — |
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $350.78, down 1.36% on the day, with a bullish technical outlook supported by moving averages and strong institutional support. The company reported $159.51B in revenue for 2025 with solid profitability metrics including 8.41% net margin and 128.38% ROE. Recent earnings show mixed results with Q2 2026 expectations at $4.73 EPS. Analyst consensus remains positive with 59% buy ratings and a $371.25 price target, representing 5.8% upside potential.
The stock presents a compelling long-term opportunity given strong fundamentals and analyst optimism, though near-term headwinds include weakening big-ticket demand and margin pressure from investments. Housing market sensitivity and competitive pressures remain key risks, but Pro business growth and digital initiatives provide resilience. Current valuation at 24.91 P/E appears reasonable for the quality franchise.
GeneDx Holdings Corp. (WGS) trades at $77.08, up 10.76% today, showing strong momentum despite negative profitability metrics. The stock exhibits bullish technical signals with support at $72 and resistance at $80. Recent Q2 2026 earnings beat expectations with $0.01 EPS versus -$0.19 estimate, while revenue reached $114.4 million. However, the company faces significant challenges with a -23.4% net income margin and ongoing securities class action litigation.
Investment outlook remains cautiously optimistic given strong analyst support (90.9% buy rating) and $79.25 consensus price target. Key opportunities include growing genomic testing volumes and improved operational efficiency, while risks center on profitability challenges, legal liabilities, and high valuation multiples that may not justify current fundamentals.
Trailing returns across standard periods
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →